Fig. 4

Combined treatment with palbociclib and SAHA more strongly suppressed the in vivo growth of NPC tumors than either monotherapy. A. Mice bearing Xeno23, Xeno76, and C666–1 xenografts were treated with the vehicle, palbociclib (75 mg/kg every other day), SAHA (20 mg/kg every other day) or palbociclib + SAHA. The tumor sizes were compared between groups using Student’s t-test (p < 0.0001 ****, p < 0.001***, p < 0.005**, p < 0.01*). b. Representative photos of tumor sections from Xeno23, Xeno76, and C666–1 xenografts in control and treatment groups after IHC for Ki-67. The percentage of Ki-67–positive cells was significantly lower in tumors subjected to combination treatment. The statistical analysis was calculated based on five randomly selected areas of each treated tumor section. Enlarged images of tissue sections subjected to IHC are presented in Supplementary Figure S9. c. Average body weights of Xeno23 tumor-bearing mice during the treatment period